Chugai To Invest U.S.$158.3 Million In Singapore Antibody Research Lab
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceuticals says it plans to invest U.S.$158.3 million on antibody research in Singapore over the next five years, beginning with the opening of a U.S.$1.2 million research institute, Chugai Pharmabody Research.